Original Report

Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32


 

Background The impact of arm morbidity following breast cancer surgery on patient-observed changes in daily functioningand health-related quality of life (HRQoL) has not been well-studied.

Objective To examine the association of objective measures such as range of motion (ROM) and lymphedema, with patient-reported outcomes (PROs) in the arm and breast, upper extremity function, activities, and HRQoL.

Methods The National Surgical Adjuvant Breast and Bowel Project Protocol B-32 was a randomized trial comparingsentinel node resection (SNR) with axillary dissection (AD) in women with node-negative breast cancer. ROM and armvolume were measured objectively. PROs included symptoms; arm function; limitations in social, recreational, occupational,and other regular activities; and a global index of HRQoL. Statistical methods included cross-tabulations and multivariablelinear regression models.

Results In all, 744 women provided at least 1 postsurgery assessment. About one-third of the patients experienced arm mobility restrictions. A similar number of patients avoided the use of the arm 6 months after surgery. Limitations in work and other regular activities were reported by about a quarter of the patients. In this multivariable analysis, arm mobility and sensory neuropathy were predictors of patient-reported arm function and overall HRQoL. Predictors for activity limitations also included side of surgery (dominant vs nondominant). Edema was not significant after adjustment for sensory neuropathy and ROM.

Limitations Arm mobility and edema were measured simultaneously only once during the follow-up (6 months).

Conclusion Clinical measures of sensory neuropathy and restrictions in arm mobility following breast cancer surgery are associated with self-reported limitations in activity and reductions in overall HRQoL.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Ki67 in pretreatment breast biopsy predicts prognosis
MDedge Hematology and Oncology
Neoadjuvant chemo renders SLN biopsy less reliable
MDedge Hematology and Oncology
HER2 status best predicts benefit of anti-HER2 therapy
MDedge Hematology and Oncology
Minimally invasive breast biopsy lags in Texas
MDedge Hematology and Oncology
New tool predicts late recurrence in breast cancer
MDedge Hematology and Oncology
Some HER2-negative cancers may benefit from anti-HER2 therapy
MDedge Hematology and Oncology
Breast-conserving therapy improved survival over mastectomy
MDedge Hematology and Oncology
Kadcyla wins FDA approval for late-stage breast cancer
MDedge Hematology and Oncology
Metastatic breast cancer incidence is rising among young women
MDedge Hematology and Oncology
Cost-benefit analysis of decision support methods for patients with breast cancer in a rural community
MDedge Hematology and Oncology